Rheumatoid Arthritic Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and other European countries. We report the prevalence of RA pain for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s RA pain forecast will answer the following questions:
- Of all people diagnosed with RA pain, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RA pain over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts two RA pain patient populations, as follows:
- Diagnosed prevalent cases of RA joint pain.
- Diagnosed drug-treated prevalent cases of RA joint pain.
Note: Coverage may vary by country.
